Secondly, we aimed to adjust for demographic and tumour-related factors and benchmark long-term survival rates in HER2-positive early-stage breast cancer patients between Stockholm-Gotland and Skane, Sweden's two largest healthcare regions. This evidence concerns the gene ERBB2 and breast cancer.